We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...

Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the ...

ALAMEDA, Calif., February 20, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 ...

Our proprietary system currently recommends Exelixis (EXEL) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks ...

Exelixis authorized a $500M stock repurchase, adding to the $1.2B returned to shareholders, with buybacks set to begin after Q2 2025. Q4 results topped estimates, with EPS at $0.55 (vs.